My Dashboard
Fin. Planning
Our Solutions
Stocks
Funds
Invest in the best stock opportunities right now and every-time.
Start Systematic Stock Investing ...in less than a minute.
BSE: 532391 | NSE: OPTOCIRCUI | Medical Equipment/Supplies/Accessories | Small Cap
1. Is Opto Circuits (India) Ltd a good quality company?
Past 10 year’s financial track record analysis by Moneyworks4me indicates that Opto Circuits (India) Ltd is a below average quality company.
2. Is Opto Circuits (India) Ltd undervalued or overvalued?
The key valuation ratios of Opto Circuits (India) Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone.
3. Is Opto Circuits (India) Ltd a good buy now?
The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Opto Circuits (India) Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
Value Creation ⓘValue Creation Index Colour Code Guide ⓘ |
|||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar'11 | Mar'12 | Mar'13 | Mar'14 | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | TTM | |||
| ROCE % ⓘ | 17.9% | 14.2% | 12.5% | 3.5% | -1.3% | 0.2% | -20% | 0.7% | 2% | -31.2% | - | ||
| Value Creation Index ⓘ | 0.3 | 0.1 | -0.1 | -0.8 | -1.1 | -1.0 | -2.4 | -1.0 | -0.9 | -3.2 | - | ||
Growth Parameters ⓘGrowth Parameters Colour Code Guide ⓘ |
|||||||||||||
| Sales ⓘ | 603 | 670 | 699 | 263 | 146 | 76.7 | 50.4 | 63.5 | 105 | 62.6 | 0 | ||
| YoY Gr. Rt. % | - | 11% | 4.4% | -62.4% | -44.4% | -47.5% | -34.3% | 26% | 65.2% | -40.3% | - | ||
| Adj EPS ⓘ | 9.8 | 9.7 | 10 | 1.8 | -2.9 | -0.7 | -15 | 0.3 | 1.1 | -11.6 | -5.3 | ||
| YoY Gr. Rt. % | - | -1.4% | 3.7% | -82.1% | -263.7% | NA | NA | NA | 220.6% | -1163.3% | - | ||
| BVPS (₹) ⓘ | 43.9 | 50.1 | 60 | 61.8 | 53 | 52.3 | 36.8 | 39.1 | 39.1 | 1.3 | -4 | ||
| Adj Net Profit ⓘ | 238 | 234 | 243 | 43.3 | -70.9 | -18 | -364 | 9.8 | 32.7 | -349 | -159 | ||
| Cash Flow from Ops. ⓘ | 118 | -29.5 | -92.9 | -15.7 | 55.7 | 335 | 57.4 | 46.6 | 42 | 21.3 | - | ||
| Debt/CF from Ops. ⓘ | 6.1 | -22.3 | -8.8 | -56 | 15.9 | 2.1 | 12.4 | 11.8 | 12.6 | 23 | - | ||
CAGR ⓘCAGR Colour Code Guide ⓘ |
||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 9 Years | 5 Years | 3 Years | 1 Years | |||||||||
| Sales ⓘ | -22.3% | -15.6% | 7.5% | -40.3% | ||||||||
| Adj EPS ⓘ | -201.9% | NA | NA | -1163.3% | ||||||||
| BVPS ⓘ | -32.4 | -52.4 | -67.2 | -96.7 | ||||||||
| Share Price | -24.2% | -29.7% | -42.1% | - | ||||||||
Key Financial Parameters ⓘPerformance Ratio Colour Code Guide ⓘ |
||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar'11 | Mar'12 | Mar'13 | Mar'14 | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | TTM | ||
| Return on Equity % ⓘ | 24.7 | 20.6 | 18.2 | 2.9 | -5.1 | -1.4 | -33.7 | 1 | 2.8 | -57.4 | 389.7 | |
| Op. Profit Mgn % ⓘ | 40 | 41.7 | 39.4 | 43.7 | 36.5 | 30.6 | 29.8 | 31.8 | 39.8 | 26.9 | -4905.1 | |
| Net Profit Mgn % ⓘ | 39.4 | 35 | 34.7 | 16.5 | -48.5 | -23.5 | -722.8 | 15.5 | 31.2 | -556.7 | -63493.1 | |
| Debt to Equity ⓘ | 0.7 | 0.5 | 0.6 | 0.6 | 0.7 | 0.6 | 0.8 | 0.5 | 0.5 | 12.5 | - | |
| Working Cap Days ⓘ | 375 | 609 | 906 | 2,774 | 4,958 | 8,646 | 10,239 | 6,471 | 3,949 | 4,624 | 1,89,400 | |
| Cash Conv. Cycle ⓘ | 234 | 264 | 360 | 1,308 | 2,330 | 2,263 | 734 | 401 | 3 | -122 | 0 | |
Return on Equity has increased versus last 3 years average to 389.70%
Sales growth has been subdued in last 3 years 7.51%
Debt to equity has increased versus last 3 years average to 12.53
Sales growth is not so good in last 4 quarters at -93.75%
| Standalone | Consolidated | |
|---|---|---|
| TTM EPS (₹) | -5.3 | -4.3 |
| TTM Sales (₹ Cr.) | 0.3 | 106 |
| BVPS (₹.) ⓘ | -4 | -7.7 |
| Reserves (₹ Cr.) ⓘ | -421 | -531 |
| P/BV ⓘ | -0.44 | -0.23 |
| PE ⓘ | 0.00 | 0.00 |
| From the Market | |
|---|---|
| 52 Week Low / High (₹) | 1.78 / 1.94 |
| All Time Low / High (₹) | 1.45 / 262.90 |
| Market Cap (₹ Cr.) | 53.5 |
| Equity (₹ Cr.) | 300.6 |
| Face Value (₹) | 10 |
| Industry PE ⓘ | 49.8 |
| Pledged * | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Opto Circuits India (OCI), incorporated in the year 1992 is a multinational medical device company headquartered out of Bengaluru, India. The company designs, develop, manufacture, market and distribute a range of medical products that are used by healthcare establishments in more than 150 countries. The manufacturing is backed by a complete range of inspection and reliability testing equipments such as Bond Pull, Shear Testers, Stereo Microscopes, IR Viewers Spectrometers and many more.
OCI specialize in cardiac and vital signs monitoring, emergency cardiac care, vascular treatments and sensing technologies. Its products are US FDA listed and CE marked. Some of the well-known brands marketed by the company are Criticare Systems, Mediaid, Unetixs Vascular, Eurocor and Cardiac Science.
The company has customers in USA, Europe, Middle East, Far East, South Africa etc. To service these customers it has offices through its subsidiaries in USA, Germany, Singapore and Dubai. It has subsidiaries namely Mediaid Inc (USA), Eurocor Gmbh (Germany), Criticare Systems Inc (USA), Advanced Micronic Devices (India), Devon Innovations (India), ORMED Medical Technology (India) and Altron Industries (India).
It clients includes names like Manipal Groups of hospitals, Escorts Heart Hospital, Wockhardt Heart Hospitals, Apollo Group of Hospitals, Lilavati hospital, Breach Candy Hospital are among others.
In January 2009, the company’s California-based Mediaid Inc., the subsidiary company and the international marketing arm of the company had received Brazilian FDA agency - Agencia Nacional de Vigilancia Sanitaria (ANVISA) - approval for marketing and sale of the Mediaid brand of US FDA-approved Pulse Oximetry (SPO2) products (Patient Monitors & Sensors) in the country and surrounding geographies.
During December, 2010 Opto Circuits (India) has successfully acquired 76% of outstanding common stock of Cardiac Science Corporation US. The company plans to exercise its top-up option under the terms of the merger agreement. The merger is expected to occur in the next few days. Following the merger, Cardiac Science will become a wholly-owned subsidiary of Opto Circuits (India).
Products
Health Care products- Under this segment it manufactures Pulse Oximeters, Pulse Oximeter Sensors, Fluid warmers, Digital Thermometer,Cholesterol Monitors And Stent.
Opto Electronics products- The Company manufactures Infrared Emitters, Infra Red Detectors, Photo Sensor, Detector and Emitter Assemblies.
Recognition
The company has ISO 9001-2000 and ISO 13485-2003 quality system certification.
OCI has received 2 Star Trading House Status in accordance with the provisions of Exim Policy of Federal Government of India.
Opto Circuits (India) has been featured in Forbes Asia’s 200 ‘Best Under a Billion’ List, 2011 by Forbes magazine. This is the third time the company has made it to this list, the last two times being 2008 and 2009.
Milestones
2010
- Opto Circuits acquisition of Unetixs Vascular creates strong synergies for Criticare Systems.
- Opto Circuits Successfully Completes Acquisition of Cardiac Science.
- Opto Circuits forays into manufacturing of cardiac stents - acquires Kolkata based N.S. Remedies.
2011
- Opto Circuits presents Bangalore Metro Rail Corporation Ltd. it's first public access defibrillator.
- Opto Circuits launches campaign to promote heart safe environments on World Heart Day.
- Opto Circuits ranked amongst Forbes' Asia's 200 Best Under a Billion companies for third year.
2012
- Opto Circuits launches new Powerheart G5 AED.
- Opto Circuits Supplies AEDs to 2012 UEFA European Football Championship.
- Opto Circuits launches its first Sirolimus Drug Eluting Stent."
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Download APP
